# Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

Source: https://onco.cc/trials/nct07288177/  
OnCo record `nct07288177` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Rinatabart sesutecan in non-small-cell lung cancer and small-cell lung cancer, run by Genmab, now recruiting.

## Summary

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT07288177 by Genmab, with 240 participants planned, started 2026-01-30 and due to reach its primary completion in 2027-11-22. Interventions recorded: Rina-S. Conditions listed: Non-small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07288177
- Phase: 2
- Setting: A Phase 2, Open-label, Multicohort Study of Rinatabart Sesutecan (Rina-S) in Participants With Non-Small Cell Lung Cancer
- Sponsor: Genmab
- Enrolled: 240

## Sources

- ClinicalTrials.gov NCT07288177: https://clinicaltrials.gov/study/NCT07288177

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Rinatabart sesutecan](https://onco.cc/drugs/rinatabart-sesutecan/)
- companies: [Genmab](https://onco.cc/companies/genmab/)

---
JSON: https://onco.cc/api/v1/entities/nct07288177.json